Somewhat Positive Media Coverage Somewhat Unlikely to Affect ContraFect (CFRX) Stock Price

Media coverage about ContraFect (NASDAQ:CFRX) has trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. ContraFect earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.6857323079773 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of ContraFect (NASDAQ CFRX) opened at $1.10 on Monday. The stock has a market capitalization of $81.02, a price-to-earnings ratio of -5.79 and a beta of -0.85. ContraFect has a 1-year low of $0.80 and a 1-year high of $2.50.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect ContraFect (CFRX) Stock Price” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/12/25/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-contrafect-cfrx-stock-price.html.

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Insider Buying and Selling by Quarter for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit